HIPEC in Secondary Cytoreductive Surgery: A Phase II trial with Oliver Zivanovic&Roisin O'Cearbhaill

BMJ talk medicine

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Drs. Oliver Zivanovic and Roisin O'Cearbhaill. Dr. Roisin O’Cearbhaill, MD, is a medical oncologist and the Research Director of the Gynecologic Medical Oncology Service and the Clinical Director of the Solid Tumor Program, Cellular Therapy Service at Memorial Sloan Kettering Cancer Center, with a joint faculty appointment at Weill Cornell Medical College. Nationally, she serves as the Chair, Developmental Therapeutics, NRG Oncology. Dr. Oliver Zivanovic MD is a Gynecologic Oncologist at the Department of Surgery at Memorial Sloan Ketteting Cancer Center with a joint faculty appointment at Weill Cornell Medical College. He serves as the Institutional Principle Investigator for NRG Oncology. @ROCearbhaill / @zivanovicmd / @TeamOvary_MSK / @sloan_kettering Highlights: -HIPEC with carboplatin at secondary cytoreductive surgery for first platinum-sensitive recurrent ovarian cancer was not superior to secondary cytoreduction without HIPEC. -HIPEC for recurrent ovarian cancer should be conducted in the setting of a clinical trial